ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Regulus Therapeutics has granted Sanofi an exclusive license for RG-012, a microRNA therapeutic in a Phase II study for a genetic kidney disease called Alport syndrome. Running low on cash, Regulus in July laid off 60% of its staff and paused recruitment for the RG-012 trial while it reconfigured its long-standing partnership with Sanofi. The French drug firm will pay roughly $7 million for full rights to RG-012 and reimburse Regulus for some activities.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X